Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZENITH TARGETING LAUNCH OF INJECTABLES FOR LATE 1987

Executive Summary

ZENITH TARGETING LAUNCH OF INJECTABLES FOR LATE 1987, the company announced in an Oct. 9 release. Zenith said it hopes to have a line of sterile products, including injectables, "reach approximately 20 different products in the first two years of operation." The company purchased its sterile manufacturing facilities from Smith Labs. "We anticipate that these product introductions will begin to occur in the latter part of 1987," Zenith stated. The company said it has not yet submitted an ANDA for any injectable product. In the interim before approval of its own line, Zenith will perform contract manufacturing. Zenith announced that it has a contract with Boots for manufacture of chymopapain. Boots acquired the herniated disc product when it purchased Baxter Travenol's Flint Labs subsidiary in August. Baxter was manufacturer of the Discase brand of chymopapain; it acquired the rights to Smith Labs' Chymodiactin brand in July. Zenith completed its purchase of Smith Lab's sterile product manufacturing facilities on Sept. 30. Zenith earlier noted that the acquisition would enable the company to expand its pharmaceutical line to include injectable products ("The Pink Sheet" May 26, T&G-12). Smith Labs had also commented that it might consider a contract production agreement with Zenith at some time in the future. Boots will carry out that plan. Zenith said it is also negotiating with other companies for contract manufacturing. In the same release, Zenith predicted a net after-tax loss for the third quarter ended Sept. 30 that "should not exceed approximately $3.5 mil." The company stated: "In response to these losses, Zenith has implemented special sales promotions and cost reduction programs, including major work force reductions." Zenith said it has laid off approximately 25% of its employees, cutting the total work force to less than 400. The firm explained that some of those laid off will return to work while there will be reductions in other areas.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel